Prosecution Insights
Last updated: July 14, 2026
Application No. 19/053,238

BALLOON CATHETER AND METHODS OF USE TO REDUCE RESIDUAL STENOSIS

Non-Final OA §DP
Filed
Feb 13, 2025
Priority
Jun 24, 2022 — provisional 63/355,324 +1 more
Examiner
DANG, ANH TIEU
Art Unit
3771
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Cagent Vascular Inc.
OA Round
4 (Non-Final)
65%
Grant Probability
Favorable
4-5
OA Rounds
1y 11m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 65% — above average
65%
Career Allowance Rate
422 granted / 646 resolved
-4.7% vs TC avg
Strong +36% interview lift
Without
With
+35.8%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
34 currently pending
Career history
685
Total Applications
across all art units

Statute-Specific Performance

§101
0.2%
-39.8% vs TC avg
§103
75.1%
+35.1% vs TC avg
§102
14.2%
-25.8% vs TC avg
§112
3.0%
-37.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 646 resolved cases

Office Action

§DP
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after allowance or after an Office action under Ex Parte Quayle, 25 USPQ 74, 453 O.G. 213 (Comm'r Pat. 1935). Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, prosecution in this application has been reopened pursuant to 37 CFR 1.114. Applicant's submission filed on June 17, 2026 has been entered. Information Disclosure Statement The information disclosure statement (IDS) submitted on June 3, 2026 and June 17, 2026 was filed after the mailing date of the Notice of Allowance on March 4, 2026. The submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claim 2 provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claim 2 of copending Application No. 19578371 (reference application) in view of Thielen et al (US 20110264039) and Melsky et al (US 20180193612). Although the claims at issue are not identical, they are not patentably distinct from each other because Application 19578371 claim 2 recites the claimed catheter, plurality of pumps, and plurality of wedge dissectors, wherein Thielen et al (hereafter Thielen) teaches a pump connected to a balloon and acting on a liquid medium used to fill the balloon, wherein the pump is configured to produce hydraulic waves for calcium fracturing (paragraph 0077-0078). Therefore, it would have been obvious to one with ordinary skill in the art at the time of the invention to substitute the hydraulic wave energy source in the reference application with a pump configured to produce hydraulic waves for calcium fracturing as taught by Thielen, as an art-recognized equivalent hydraulic wave energy source for calcium fracturing at the time of the invention and it has been held that mere substitution of art-recognized equivalents involves routine skill in the art. Grace in view of Thielen do not specifically teach a plurality of pumps connected to the balloon and acting on a liquid medium used to fill the balloon. Melsky et al (hereafter Melsky) teaches it was known in the art at the time of the invention for a fluid management system for a balloon catheter to utilize a plurality of pumps in order to rapidly inflate and deflate a balloon (paragraph 0036). Therefore, it would have been obvious to one with ordinary skill in the art at the time of the invention to include an additional plurality of pumps connected to the balloon and acting on a liquid medium used to fill the balloon as part of a balloon inflation media management system, as taught by Melsky, in order to maintain a desired pressure of the balloon while maintaining adequate fluid flow to cool the balloon). This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to ANH TIEU DANG whose telephone number is (571)270-3221. The examiner can normally be reached Monday-Thursday (9am-4pm EST). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Darwin Erezo can be reached at (571) 272-4695. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ANH T DANG/Primary Examiner, Art Unit 3771
Read full office action

Prosecution Timeline

Show 5 earlier events
Jul 15, 2025
Final Rejection mailed — §DP
Nov 13, 2025
Request for Continued Examination
Nov 25, 2025
Response after Non-Final Action
Dec 03, 2025
Non-Final Rejection mailed — §DP
Jan 09, 2026
Response Filed
Jun 03, 2026
Request for Continued Examination
Jun 16, 2026
Response after Non-Final Action
Jul 01, 2026
Non-Final Rejection mailed — §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12672860
MEDICAL SNARE DEVICE
3y 2m to grant Granted Jul 07, 2026
Patent 12667358
INCISIONLESS GASTRIC BYPASS SYSTEM
3y 3m to grant Granted Jun 30, 2026
Patent 12667383
ULTRASONIC SURGICAL INSTRUMENT AND METHOD OF LATERALLY ALIGNING BLADE WITH CLAMP ARM
2y 0m to grant Granted Jun 30, 2026
Patent 12661136
METHODS, SYSTEMS AND DEVICES FOR GENERATING PRESSURE WAVES IN INTRAVASCULAR LITHOTRIPSY
4y 7m to grant Granted Jun 23, 2026
Patent 12648788
ENDOVASCULAR DEVICES AND METHODS FOR EXPLOITING INTRAMURAL SPACE
4y 10m to grant Granted Jun 09, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

4-5
Expected OA Rounds
65%
Grant Probability
99%
With Interview (+35.8%)
3y 4m (~1y 11m remaining)
Median Time to Grant
High
PTA Risk
Based on 646 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month